Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung Cancers


Release Date: November 30, 2018
Expiration Date: November 30, 2019
Media: Internet - based

Activity Overview

This online Physicians’ Education Resource, LLC, (PER®) activity, Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung Cancers, is designed to update physicians on data presented at the World Conference on Lung Cancer, which took place September 23-26, 2018, in Toronto, Canada. During this online activity, the program faculty, Karen Reckamp, MD, MS, will review 3 abstracts chosen as the most clinically relevant to facilitate integration of cutting-edge data into practice. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Benefits of Participating

  • Increased knowledge of recent cutting-edge clinical trial results that impact treatment of patients with lung cancer
  • Hear expert perspectives on the clinical context of emerging data from the World Conference on Lung Cancer
  • Identify key ongoing clinical trials for patients with small cell lung cancer, ALK mutation–positive non-small cell lung cancer (NSCLC), and locally advanced stage III NSCLC

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, pulmonologists, and nurses involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  • Detail the design, efficacy, and safety readouts of presented completed and ongoing clinical trials evaluating novel treatment strategies in the setting of advanced lung cancer
  • Integrate recent trial safety and efficacy results in the context of evolving treatment paradigms for the treatment of lung cancer
  • Identify planned/ongoing clinical trials intended to address remaining unanswered clinical questions in the field of advanced lung cancer management

Faculty, Staff, and Planners' Disclosures

Faculty

Karen L. Reckamp, MD, MS
Professor
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
 

Disclosures: Grant/Research Support: AbbVie, Acea, Adaptimmune, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Guardant, Janssen, Loxo Oncology, Seattle Genetics, Takeda, Xcovery, Zeno; Consultant: Boehringer Ingelheim, Euclises, Exelixis, Guardant, Genentech, Loxo, Precision Health, Seattle Genetics, Takeda, Tesaro

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.







Become a Member

Forgot Password?
Filter By